Pacing Characteristics of a Conventional Bipolar
Symptomatic Bradycardia
About this trial
This is an interventional treatment trial for Symptomatic Bradycardia focused on measuring FF068, Conventional bipolar, symptomatic bradycardia, left bundle branch area pacing, LBBAP
Eligibility Criteria
Inclusion Criteria: Adult patients ≥ 20 years of age Standard bradycardia pacing indications requiring new ventricular lead implantation Able to give informed consent for the participation in the trial Exclusion Criteria: Patients underwent cardiac resynchronization therapy or implantable cardioverter-defibrillator implantation New York Heart Association (NYHA) functional class IV heart failure Life expectancy < 1 year Right-sided approach for lead implantation Hemodialysis or peritoneal dialysis patients Pregnant or breast-feeding women Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints Participation in another prospective interventional clinical study within a period of 4 weeks prior to the implantation of LBBAP Use of any recreational drugs or history of drug addiction Any other condition that, in the investigator's judgment, might increase the risk to the patients or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study
Sites / Locations
- Chang Gung Memorial Hospital
Arms of the Study
Arm 1
Other
Solia S lead with any BIOTRONIK Pacemaker
Name: Solia S lead with any BIOTRONIK Pacemaker Model: Solia S45/S53/S60 Manufacturer: BIOTRONIK SE & Co. KG Method of use: LBBAP implantation for all bradycardia indications. Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony. Device category and grade: E3610 Cardiovascular devices, Class III